Abstract
The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature. Patients (n < 187) scheduled for coronary artery bypass surgery used study medication 27 ± 1 days before surgery. Segments of internal mammary arteries were exposed to increasing doses (0.1 nM-1 µM) of angiotensin I and II in organ baths. The rate of local angiotensin II formation is a function of the reciprocal of the difference between the pEC50's of the dose response curves to angiotensin I and II (−log/mol) and of the area between the curves (units). Quinapril (40 mg) and captopril (3×50 mg) similarly and significantly reduced mean blood pressure compared with placebo (p = 0.04). Difference between pEC50's was 0.90 ± 0.08 in quinapril patients compared with 0.60 ± 0.08 for placebo (p <5 0.01); the area between curves was 91 ± 8 for quinapril patients compared with 67 ± 8 for placebo (p = 0.03). Angiotensin II formation was decreased to a lesser extent with captopril and was not statistically different from placebo (p = 0.3); the difference between pEC50's was 0.83 ± 0.15; the area between curves was 84 ± 12. This is the first randomized study to demonstrate that long-term oral treatment with an ACE inhibitor reduces vascular angiotensin II formation in humans.
Similar content being viewed by others
References
Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-559.
Lindpaintner K, Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res 1991;68:905-921.
Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66: 22D-32D.
Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue specific activation of cardiac angiotensin-converting enzyme in experimental heart failure. Circ Res 1991;69:475-482.
Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15.
Schiffrin EL, Deng LY, Larochelle P. A prospective trial of effects of converting enzyme inhibitor vs a beta-blocker on structure and function of resistance arteries form mild hypertensive patients. J Hypertens 1994;12(Suppl. 3):S70-S88.
Nakashima Y, Fouad FM, Tarazi RZ. Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044-1049.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987;316:1429-1435.
Buikema H, Pinto YM, Rooks G, Grandjean JG, Gilst van WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17:787-794.
Buikema H, Pinto YM, Geel van PP, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol 1997;29:684-691.
Voors AA, Pinto YM, Buikema H, et al. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-1032.
Long Zhuo J, Froomes P, Casley D, et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997;96: 174-182.
Mancini J, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND study. Circulation 1996;94:258-265.
Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1989;40:360-369.
Nussberger J, Waeber G, Waeber B, Bidiville J, Brunner HR. Plasma angiotensin-(1-8) octapeptide measurement to assess acute angiotensin-converting enzyme inhibition with captopril administered parenterally to normal subjects. J Cardiovasc Pharmacol 1988;11:716-721.
Schnaper HW. Comparison of the efficacy and safety of quinapril vs captopril in treatment of moderate to severe hypertension. Angiology 1989;40:389-395.
Okunishi H, Oka Y, Shioto N, Kawanoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathway: Humans versus rodents. Jpn J Pharmacol 1993;62:207-210.
Skidgel RA, Erdos EG. Biochemistry of angiotensin converting enzyme. In: Robertson HS, Nicolls MG, eds. The Renin-Angiotensin System. London: Gower Medical Publishers, 1993.
Gavras I. Bradykinin-mediated effects of ACE-inhibition. Kidney Int 1992;42:1020-1029.
Auch-Schwelk W, Bossaller C, Claus M, Graf M, Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993;27:312-317.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oosterga, M., Voors, A.A., Buikema, H. et al. Angiotensin II Formation in Human Vasculature after Chronic ACE Inhibition: A Prospective, Randomized, Placebo-Controlled Study. Cardiovasc Drugs Ther 14, 55–60 (2000). https://doi.org/10.1023/A:1007843205311
Issue Date:
DOI: https://doi.org/10.1023/A:1007843205311